MorphoSys tanks after Celgene walks away from $818M pact

Posted: March 27th, 2015  |  Company/topic: Celgene
Celgene has walked away from its $818 million multiple myeloma co-development pact with MorphoSys less than two years after striking the deal. The decision means Celgene has nothing to show for the $9…

Analyst: First Quarter Market Meltdown Just “Clockwork,” As Biogen, Celgene Reign

Posted: March 25th, 2015  |  Company/topic: Celgene
March 26, 2015By Riley McDermid…

Pharmalot.. Pharmalittle.. Good Morning: We’re Catching Up On Celgene, Sanofi and Lots More!!

Posted: March 19th, 2015  |  Company/topic: Celgene
Associated Press Rise and shine. Another busy day is on the way. A bright, warm sun is enveloping the Pharmalot campus this morning, as we prepare for the latest attempt at tackling our ever-growing…

Crohn’s expert flags blockbuster potential–and frets–of Celgene’s mongersen

Posted: March 19th, 2015  |  Company/topic: Celgene
Celgene just got both an endorsement as well as a few challenges in a review of the midstage study for mongersen, an experimental drug for Crohn's disease that will soon be part of the big biotech's l…